Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ · Manufacturing · Pharmaceutical preparations
CTNM price, last 12 months
Key stats
- Previous close
- $9.24
- Open
- $9.54
- Day range
- $8.92 – $9.63
- 52-week range
- $6.73 – $17.79
- Volume
- 197.7K
- Avg volume (20 days)
- 406.3K
- Market cap
- $387.2M
Performance
Technicals and fundamentals
About Contineum Therapeutics, Inc. Class A
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $387.2M